0 0 0 -6.33071663711756E-05 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Why Biogen Stock Rose 14.7% in February [The Motley Fool]

Biogen Inc. (BIIB)  More Company Research Source: The Motley Fool
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Why Biogen Stock Rose 14.7% in February Investors cheer as Biogen wins a patent ruling involving its blockbuster multiple sclerosis drug. Shares of Biogen ( NASDAQ:BIIB ) rose 14.7% in February, according to data provided by S&P Global Market Intelligence , after the company won a patent ruling concerning its blockbuster multiple sclerosis drug. In a case brought by generic-drug maker Mylan ( NASDAQ:MYL ) , the U.S. Patent and Trademark Office's patent trial and appeal board ruled in Biogen's favor. That means Biogen's Tecfidera won't face competition until patent expiration in 2028 -- unless a Mylan appeal or other separate patent challenges result in a different decision. In the fourth quarter, Tecfidera accounted for 40% of Biogen's product revenues, so news upholding its patent, and therefore blocking generic competition, is positive. This gives Biogen time to ramp up sales of its new MS drug, Vumerity, in the coming quarters. A fumarate drug like Tecfidera, Vumerity offers the [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Why Biogen Stock Rose 14.7% in February [The Motley Fool]

Biogen Inc.  (BIIB) 
More Company Research Source: The Motley Fool
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Why Biogen Stock Rose 14.7% in February Investors cheer as Biogen wins a patent ruling involving its blockbuster multiple sclerosis drug. Shares of Biogen ( NASDAQ:BIIB ) rose 14.7% in February, according to data provided by S&P Global Market Intelligence , after the company won a patent ruling concerning its blockbuster multiple sclerosis drug. In a case brought by generic-drug maker Mylan ( NASDAQ:MYL ) , the U.S. Patent and Trademark Office's patent trial and appeal board ruled in Biogen's favor. That means Biogen's Tecfidera won't face competition until patent expiration in 2028 -- unless a Mylan appeal or other separate patent challenges result in a different decision. In the fourth quarter, Tecfidera accounted for 40% of Biogen's product revenues, so news upholding its patent, and therefore blocking generic competition, is positive. This gives Biogen time to ramp up sales of its new MS drug, Vumerity, in the coming quarters. A fumarate drug like Tecfidera, Vumerity offers the [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS